Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myriam Labopin

Showing results (151-160 of 443) with videos related to

Pageof 45
Sort By:
Bone Marrow Transplantation|February 6, 2019
Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMTGiorgia Battipaglia, Ariane Boumendil, Myriam Labopin, et al.
American Journal of Hematology|March 3, 2018
T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationJonathan Canaani, Myriam Labopin, Xiao-Jun Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2007
Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working PartyChristoph Schmid, Myriam Labopin, Arnon Nagler, et al.
Bone Marrow Transplantation|April 18, 2018
Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemiaGiorgia Battipaglia, Annalisa Ruggeri, Myriam Labopin, et al.
Transplantation|May 7, 2014
Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?Olle Ringdén, Myriam Labopin, Martin Solders, et al.
Bone Marrow Transplantation|September 6, 2020
Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMTSebastian Giebel, Myriam Labopin, Malgorzata Sobczyk-Kruszelnicka, et al.
Bone Marrow Transplantation|July 11, 2021
Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMTFrédéric Baron, Maud Ngoya, Myriam Labopin, et al.
Blood Cancer Journal|April 14, 2019
Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMTFrédéric Baron, Myriam Labopin, Annalisa Ruggeri, et al.
Journal of Hematology & Oncology|October 25, 2019
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMTJiří Pavlů, Myriam Labopin, Riitta Niittyvuopio, et al.
British Journal of Haematology|February 6, 2020
Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remissionMarina Díaz-Beyá, Myriam Labopin, Johan Maertens, et al.
Pageof 45

Showing results (151-160 of 443) with videos related to

Sort By:
Pageof 45
Bone Marrow Transplantation|February 6, 2019
Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMTGiorgia Battipaglia, Ariane Boumendil, Myriam Labopin, et al.
American Journal of Hematology|March 3, 2018
T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationJonathan Canaani, Myriam Labopin, Xiao-Jun Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2007
Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working PartyChristoph Schmid, Myriam Labopin, Arnon Nagler, et al.
Bone Marrow Transplantation|April 18, 2018
Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemiaGiorgia Battipaglia, Annalisa Ruggeri, Myriam Labopin, et al.
Transplantation|May 7, 2014
Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?Olle Ringdén, Myriam Labopin, Martin Solders, et al.
Bone Marrow Transplantation|September 6, 2020
Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMTSebastian Giebel, Myriam Labopin, Malgorzata Sobczyk-Kruszelnicka, et al.
Bone Marrow Transplantation|July 11, 2021
Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMTFrédéric Baron, Maud Ngoya, Myriam Labopin, et al.
Blood Cancer Journal|April 14, 2019
Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMTFrédéric Baron, Myriam Labopin, Annalisa Ruggeri, et al.
Journal of Hematology & Oncology|October 25, 2019
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMTJiří Pavlů, Myriam Labopin, Riitta Niittyvuopio, et al.
British Journal of Haematology|February 6, 2020
Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remissionMarina Díaz-Beyá, Myriam Labopin, Johan Maertens, et al.
Pageof 45